| Name | Title | Contact Details |
|---|---|---|
Suresh Namala |
Executive Director, IT Risk and Compliance | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
BIOWEST THERAPEUTICS Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Canadian Light Source is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Enzyme Technologies Limited is engaged in business of manufacturing and sale of enzymes. The Companys geographical segments include Within India and Outside India. It provides solutions to industries, such as human healthcare and nutrition, a...
Ask Linda Pet Sitting is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.